The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final 24-Month Primary Endpoint Analysis
Diabetologie und Stoffwechsel（2023）
摘要
Question How long do people with Type 2 Diabetes (T2D) remain on their first glucagon-like peptide-1 receptor agonists (GLP-1 RA) without a significant treatment change?
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要